RESUMEN
The family of EUL-related lectins groups all proteins with an Euonymus lectin (EUL) domain, a protein motif which is highly conserved throughout the plant kingdom and occurs as part of many chimeric proteins with different domain architectures. The S3 type EUL lectin from Arabidopsis thaliana (ArathEULS3) has become the model protein within this EUL family. Based on sequence homology to an ABA/NaCl inducible gene from rice and some publicly available high-throughput micro-array data, it was hypothesized that ArathEULS3 is transcriptionally regulated by osmotic stress responses. Here we present a detailed expression analysis of the ArathEULS3 lectin gene. Under normal growth conditions, ArathEULS3 is stably expressed throughout plant development. After ABA, NaCl and methyl jasmonate (MeJA) treatments transcription is upregulated. Furthermore, in silico promoter and co-expression analyses suggested the A. thaliana Homeobox 7 (ATHB-7) as a candidate transcription factor that may regulate ArathEULS3 expression. Taken together, our data confirm that the ArathEULS3 lectin gene indeed shows a stress-inducible expression pattern. We speculate on a role for ArathEULS3 in the plant stress response.
Asunto(s)
Proteínas de Arabidopsis/genética , Arabidopsis/fisiología , Perfilación de la Expresión Génica , Estrés Fisiológico , Transcripción Genética , Arabidopsis/genética , Arabidopsis/crecimiento & desarrollo , Secuencia de Bases , Cartilla de ADN , Genes de Plantas , Plantas Modificadas GenéticamenteRESUMEN
Enzyme replacement therapy (ERT) with laronidase, recombinant alpha-L-iduronidase, for mucopolysaccharidosis type I (MPS I) has been clinically available since April 2003. Pre-approval studies were performed on patients with the more attenuated forms of MPS I, Hurler-Scheie and Scheie syndromes. The clinical efficacy of laronidase on the severe form of MPS I, Hurler syndrome, is not well known. We present a patient with Hurler syndrome who has been treated with laronidase for 3 years. Clinically, the patient demonstrated improvement in urinary glycosaminoglycan (GAG) levels and hepatomegaly, but continued to experience decline in respiratory status, musculoskeletal and spinal involvement, and developmental skills. Overall, the benefit of ERT with laronidase in advanced Hurler syndrome appeared to be minimal in this patient.
Asunto(s)
Iduronidasa/uso terapéutico , Mucopolisacaridosis I/tratamiento farmacológico , Progresión de la Enfermedad , Glicosaminoglicanos/orina , Humanos , Factores de Tiempo , Resultado del TratamientoRESUMEN
BACKGROUND: The classic rhizomelic chondrodysplasia punctata (RCDP) phenotype involves a typical facial appearance, cataracts, skeletal dysplasia causing disproportionate somatic growth failure, microcephaly, and severe psychomotor defects. Biochemical abnormalities include impaired plasmalogen biosynthesis in all forms of RCDP and accumulation of phytanic acid in RCDP type 1. A subset of patients has a milder clinical and biochemical phenotype, with less severe neurologic impairment and an incomplete deficiency in plasmalogens. The impact of plasmalogen deficiency on neurologic function is severe, causing spasticity and mental defects, but its pathomechanism is still unknown. The authors specifically focused on myelination because myelin is rich in ethanolamine plasmalogens. OBJECTIVE: To define the neuroimaging characteristics of the genetic peroxisomal disorder RCDP. METHODS: Twenty-one MR images of the brain and cervical spine of 11 patients were evaluated and correlated with neurologic and biochemical profiles. RESULTS: No abnormalities on MRI were seen in the patients with a mild phenotype of RCDP, whereas delayed myelination, ventricular enlargement and increased subarachnoidal spaces, supratentorial myelin abnormalities, and cerebellar atrophy were observed in patients with the severe phenotype of both RCDP type 1 and 3. The severity of both the MRI abnormalities and the clinical phenotype is correlated with the plasmalogen level. CONCLUSIONS: The severe phenotype of rhizomelic chondrodysplasia punctata (RCDP) is accompanied by a specific pattern of both developmental and regressive MRI abnormalities. Plasmalogen levels seem to play an important role in the pathophysiology of CNS abnormalities in RCDP. Increased phytanic acid appears not to be the cause of cerebellar atrophy.
Asunto(s)
Encéfalo/patología , Vértebras Cervicales/patología , Condrodisplasia Punctata Rizomélica/patología , Imagen por Resonancia Magnética/estadística & datos numéricos , Médula Espinal/patología , Adulto , Encéfalo/metabolismo , Vértebras Cervicales/metabolismo , Niño , Preescolar , Condrodisplasia Punctata Rizomélica/genética , Condrodisplasia Punctata Rizomélica/metabolismo , Estudios de Cohortes , Femenino , Humanos , Lactante , Fenotipo , Médula Espinal/metabolismoRESUMEN
BACKGROUND: Segawa syndrome due to GTP cyclohydrolase deficiency is an autosomal dominant disorder with variable expression, that is clinically characterised by l-dopa responsive, diurnally fluctuating dystonia and parkinsonian symptoms. OBJECTIVE: To delineate the neurological and psychiatric phenotype in all affected individuals of three extended families. METHODS: GTP cyclohydrolase deficiency was documented by biochemical analyses, enzymatic measurements in fibroblasts, and molecular investigations. All affected individuals were examined neurologically, and psychiatric data were systematically reviewed. RESULTS: Eighteen affected patients from three families with proven GTP cyclohydrolase deficiency were identified. Eight patients presenting at less than 20 years of age had typical motor symptoms of dystonia with diurnal variation. Five family members had late-presenting mild dopa-responsive symptoms of rigidity, frequent falls, and tendonitis. Among mutation carriers older than 20 years of age, major depressive disorder, often recurrent, and obsessive-compulsive disorder were strikingly more frequent than observed in the general population. Patients responded well to medication increasing serotonergic neurotransmission and to l-dopa substitution. Sleep disorders including difficulty in sleep onset and maintenance, excessive sleepiness, and frequent disturbing nightmares were present in 55% of patients. CONCLUSION: Physicians should be aware of this expanded phenotype in affected members of families with GTP cyclohydrolase deficiency.
Asunto(s)
Distonía/enzimología , Distonía/genética , GTP Ciclohidrolasa/deficiencia , GTP Ciclohidrolasa/genética , Paraparesia Espástica/genética , Trastornos Parkinsonianos/genética , Temblor/genética , Adolescente , Adulto , Ritmo Circadiano/fisiología , Distonía/complicaciones , Femenino , Fibroblastos/enzimología , Expresión Génica , Humanos , Extremidad Inferior/fisiopatología , Masculino , Persona de Mediana Edad , Paraparesia Espástica/complicaciones , Trastornos Parkinsonianos/complicaciones , Linaje , Fenotipo , Fenilalanina/sangre , Reacción en Cadena de la Polimerasa , Reflejo Anormal , Síndrome , Tendinopatía/complicaciones , Temblor/complicacionesRESUMEN
High-dose benzoate treatment aimed at reducing plasma glycine levels to normal reduces seizures and increases wakefulness in patients with nonketotic hyperglycinaemia (NKH). Since benzoate metabolism is dependent on the available glycine pool, and since the glycine pool is variably affected by the deficiency in the glycine cleavage enzyme system, we examined the importance of interpatient variability in benzoate requirement. To correct for the dietary glycine contribution, the glycine index was introduced as the molar requirement of benzoate dose necessary to normalize plasma glycine levels and subtracting from that the dietary glycine intake, both corrected for weight. The glycine index varied between 3.62 and 4.87 mmol/kg per day in five patients with a poor neurodevelopmental outcome and between 0.92 and 1.90 mmol/kg per day in four patients with a better neurodevelopmental outcome, and was 2.54 mmol/kg per day in a single patient with an intermediate outcome. The glycine index was stable over time within each patient. Exceeding the balance by either increasing food glycine intake or decreasing the benzoate dose resulted in increased glycine levels. Exceeding the glycine tolerance by increasing benzoate resulted in elevated and toxic levels of benzoate. The glycine index is a stable, individually specific parameter in patients with NKH. It has clinical consequences for the dose of benzoate required and the role of dietary management. Through its correlation with neurodevelopmental outcome, the glycine index points to potential genetic factors that could contribute to the psychomotor retardation in NKH.
Asunto(s)
Benzoatos/uso terapéutico , Ácido Benzoico/uso terapéutico , Glicina/análisis , Hiperglicinemia no Cetósica/dietoterapia , Hiperglicinemia no Cetósica/tratamiento farmacológico , Adolescente , Factores de Edad , Edad de Inicio , Aminoácido Oxidorreductasas , Antiinfecciosos/uso terapéutico , Proteínas Portadoras , Niño , Preescolar , Dieta , Femenino , Glicina/química , Glicina/metabolismo , Humanos , Lactante , Recién Nacido , Masculino , Modelos Biológicos , Trastornos de la Destreza Motora/patología , Complejos Multienzimáticos , Benzoato de Sodio/farmacología , Factores de Tiempo , Transferasas , Resultado del TratamientoRESUMEN
BACKGROUND: Glycine encephalopathy, also known as nonketotic hyperglycinemia (NKH), is an autosomal recessive disorder caused by a defect in the glycine cleavage system. NKH is classically associated with neonatal apnea, lethargy, hypotonia, and seizures, followed by severe psychomotor retardation in those who survive. METHODS: To determine the natural history of NKH, the authors mailed a 44-question survey to 170 households in the International NKH Family Network. RESULTS: Data for 65 patients (36 boys, 29 girls) were collected from 58 families. One-third of the subjects died; 8 girls died during the neonatal period, and 14 patients died thereafter (2 girls, 12 boys). Median age of death for boys was 2.6 years vs <1 month for girls (p = 0.02). Mean birth weight and length, occipitofrontal circumference, and gestation duration were normal. Two-thirds of infants were ventilated during the neonatal period; of these, 40% died. Ninety percent had confirmed seizures, 75% during the first month of life. Interestingly, three NKH patients never developed seizures. An abnormal corpus callosum and/or hydrocephalus were associated with especially poor gross motor and speech development. Of 25 patients living > or =3 years, 10 were able to walk and say/sign words; all were boys. In six families with more than one affected child, disease course and mortality were similar within each family. CONCLUSIONS: This study reveals a striking and unexpected gender difference in mortality and developmental progress. Of the two-thirds of nonketotic hyperglycinemia patients surviving the newborn period, up to 20% (mostly boys) may learn to walk and communicate by saying or signing words.
Asunto(s)
Hiperglicinemia no Cetósica/epidemiología , Trastornos Psicomotores/etiología , Adolescente , Edad de Inicio , Agenesia del Cuerpo Calloso , Anticonvulsivantes/uso terapéutico , Apnea/etiología , Apnea/terapia , Niño , Preescolar , Progresión de la Enfermedad , Femenino , Glicina/sangre , Glicina/líquido cefalorraquídeo , Encuestas Epidemiológicas , Humanos , Hidrocefalia/epidemiología , Hidrocefalia/etiología , Hiperglicinemia no Cetósica/complicaciones , Hiperglicinemia no Cetósica/metabolismo , Hiperglicinemia no Cetósica/mortalidad , Lactante , Recién Nacido , Masculino , Epilepsia Mioclónica Juvenil/tratamiento farmacológico , Epilepsia Mioclónica Juvenil/epidemiología , Epilepsia Mioclónica Juvenil/etiología , Nistagmo Patológico/epidemiología , Nistagmo Patológico/etiología , Embarazo , Complicaciones del Embarazo/epidemiología , Trastornos Psicomotores/epidemiología , Sistema de Registros , Respiración Artificial , Estudios Retrospectivos , Convulsiones/tratamiento farmacológico , Convulsiones/epidemiología , Convulsiones/etiología , Factores Sexuales , Encuestas y Cuestionarios , Análisis de SupervivenciaRESUMEN
We present a patient with juvenile neuronal ceroid lipofuscinosis who developed a neuroleptic malignant syndrome when treated for hallucinations with a very low dose of risperidone, an atypical neuroleptic medication with usually few extrapyramidal side-effects. The loss of dopaminergic neurons in this condition may make these patients more vulnerable to this severe adverse effect.
Asunto(s)
Antipsicóticos/efectos adversos , Síndrome Neuroléptico Maligno/complicaciones , Lipofuscinosis Ceroideas Neuronales/complicaciones , Risperidona/efectos adversos , Adulto , Antipsicóticos/uso terapéutico , Creatina Quinasa/sangre , Dopamina/fisiología , Femenino , Fiebre/complicaciones , Alucinaciones/tratamiento farmacológico , Humanos , Discapacidad Intelectual , Lipofuscinosis Ceroideas Neuronales/psicología , Risperidona/uso terapéuticoRESUMEN
The authors report 1-year prospective data on eight patients with Friedreich ataxia. Idebenone did not halt the progression of ataxia. At the end of therapy, cardiac ultrasound demonstrated significant reduction of cardiac hypertrophy in six of eight patients. Cardiac strain and strain rate imaging showed that the reduction of hypertrophy is preceded by an early and linear improvement in cardiac function. Idebenone reduced erythrocyte protoporphyrin IX levels in five of six patients with elevated baseline levels; however, changes did not consistently relate to cardiac improvement.
Asunto(s)
Benzoquinonas/uso terapéutico , Depuradores de Radicales Libres/uso terapéutico , Ataxia de Friedreich/complicaciones , Hipertrofia Ventricular Izquierda/tratamiento farmacológico , Adolescente , Adulto , Benzoquinonas/farmacología , Cardiomiopatía Hipertrófica/tratamiento farmacológico , Cardiomiopatía Hipertrófica/etiología , Cardiomiopatía Hipertrófica/fisiopatología , Niño , Eritrocitos/química , Femenino , Depuradores de Radicales Libres/farmacología , Radicales Libres , Ataxia de Friedreich/sangre , Ataxia de Friedreich/genética , Ataxia de Friedreich/fisiopatología , Humanos , Hipertrofia Ventricular Izquierda/etiología , Hipertrofia Ventricular Izquierda/fisiopatología , Proteínas de Unión a Hierro/genética , Proteínas de Unión a Hierro/fisiología , Masculino , Mitocondrias/metabolismo , Estrés Oxidativo , Estudios Prospectivos , Protoporfirinas/sangre , Volumen Sistólico , Ubiquinona/análogos & derivados , FrataxinaRESUMEN
We report here a unique case of a 55-year-old woman presenting with a clinical picture of Parkinson disease, severe back pain, splenomegaly, and pronounced dyspnea. Radiographic examination of the spine showed multiple vertebral fractures. Niemann-Pick disease type B was diagnosed by findings of lipid-loaded histiocytes and a strongly reduced sphingomyelinase enzyme activity. She was homozygous for the deletion of codon 608 (delR608), which encodes an arginine residue in the Acid Sphingomyelinase gene. To investigate the cause of the unusual vertebral fractures, we screened for polymorphisms previously described as possibly associated with increased risk for osteoporosis and fractures. Our patient was heterozygous for the polymorphisms of the vitamin D receptor gene, the estrogen receptor gene, and the collagen 1A1gene. Increased physical activity after Parkinson treatment, a genetic predisposition, together with worsening disease due to interfering medications could explain the dramatic presentation of this patient. She was treated with cholesterol lowering drugs such as statins to decrease sphingomyelin synthesis, avoidance of drugs that inhibit sphingomyelinase, and bisphosphonates. No new fractures have occurred, but the interstitial lung disease has progressed.
Asunto(s)
Fracturas Espontáneas/patología , Enfermedades de Niemann-Pick/patología , Fracturas de la Columna Vertebral/patología , Secuencia de Aminoácidos , Secuencia de Bases , Colágeno Tipo I/genética , ADN/química , ADN/genética , Análisis Mutacional de ADN , Diagnóstico Diferencial , Humanos , Masculino , Persona de Mediana Edad , Datos de Secuencia Molecular , Mutación , Enfermedades de Niemann-Pick/enzimología , Enfermedades de Niemann-Pick/genética , Enfermedad de Parkinson/patología , Polimorfismo Genético , Receptores de Calcitriol/genética , Receptores de Estrógenos/genética , Esfingomielina Fosfodiesterasa/genética , Esfingomielina Fosfodiesterasa/metabolismoRESUMEN
Mucolipidosis III (Pseudo-Hurler Polydystrophy) is a rare autosomal recessively inherited Hurler-like disease. The ophthalmological findings in these patients include a triad of mild retinopathy, corneal clouding and hyperopic astigmatism. We present a patient with these ophthalmological characteristics.
Asunto(s)
Astigmatismo/etiología , Enfermedades de la Córnea/etiología , Mucolipidosis/complicaciones , Enfermedades de la Retina/etiología , Adolescente , Astigmatismo/diagnóstico , Enfermedades de la Córnea/diagnóstico , Femenino , Humanos , Enfermedades de la Retina/diagnósticoRESUMEN
Molybdenum cofactor deficiency is a rare inborn error of metabolism with generally severe symptoms, most often including neonatal seizures and severe developmental delay. We describe a patient with an unusually mild form of the disease. Two mutations in MOCS2A (molybdenum cofactor synthesis enzyme 2A) were identified: a single base change, 16C > T, that predicts a Q6X substitution on one allele and a 19G > T transversion that predicts a valine to phenylalanine substitution, V7F, on the second. It is postulated that the milder clinical symptoms result from a low level of residual molybdopterin synthase activity derived from the 19G > T allele.
Asunto(s)
Coenzimas , Metaloproteínas/deficiencia , Mutación , Sulfurtransferasas/genética , Alelos , Secuencia de Bases , Encéfalo/patología , Preescolar , Análisis Mutacional de ADN , ADN Complementario/metabolismo , Exones , Femenino , Glutamina/química , Heterocigoto , Humanos , Intrones , Imagen por Resonancia Magnética , Modelos Químicos , Datos de Secuencia Molecular , Cofactores de Molibdeno , Fenilalanina/química , PteridinasRESUMEN
Catalytic activity of oxidative phosphorylation complexes is maintained following separation by Blue Native polyacrylamide gel electrophoresis (BN-PAGE). In BN-PAGE gels, using histochemical staining methods, we have demonstrated enzymatic activity of the complexes I, II, IV, and V in heart and skeletal muscle, liver, and cultured skin fibroblasts. The combination of BN-PAGE and catalytic staining can be successfully applied for detection of complex deficiencies. Tissues from 18 patients with deficiency in the oxidative phosphorylation as detected by spectrophotometric assay were used (10 patients complex IV, three patients complex I, one patient complex II, one patient complex I+III, three patients complex I+IV). The gene defect was located in nuclear DNA in five patients and mitochondrial DNA in one patient. In samples from patients with a severe deficiency, almost complete absence of the corresponding enzyme band is observed after catalytic staining in the gel. In patients with known partial deficiency, a milder decrease of the corresponding enzyme band is demonstrated. The amount of protein in complexes I, V, and III can easily be evaluated in samples from heart and skeletal muscle after separation by BN-PAGE using silver or Coomassie staining. The protein amount in complex IV is difficult to visualize by silver staining but easier by the Coomassie technique. In samples from liver and cultured skin fibroblasts, evaluation of protein amount is more difficult due to high background staining. In these tissues, immunoblotting can be done after BN-PAGE and subsequent transfer to a nitrocellulose membrane.
Asunto(s)
Electroforesis en Gel de Poliacrilamida/métodos , Errores Innatos del Metabolismo/diagnóstico , Fosforilación Oxidativa , Adolescente , Adulto , Catálisis , Núcleo Celular/genética , Células Cultivadas , Niño , ADN Mitocondrial/genética , Humanos , Recién Nacido , Mitocondrias Hepáticas/enzimología , Mitocondrias Musculares/enzimologíaRESUMEN
Human malignant infantile osteopetrosis (arOP; MIM 259700) is a genetically heterogeneous autosomal recessive disorder of bone metabolism, which, if untreated, has a fatal outcome. Our group, as well as others, have recently identified mutations in the ATP6i (TCIRG1) gene, encoding the a3 subunit of the vacuolar proton pump, which mediates the acidification of the bone/osteoclast interface, are responsible for a subset of this condition. By sequencing the ATP6i gene in arOP patients from 44 unrelated families with a worldwide distribution we have now established that ATP6i mutations are responsible for approximately 50% of patients affected by this disease. The vast majority of these mutations (40 out of 42 alleles, including seven deletions, two insertions, 10 nonsense substitutions and 21 mutations in splice sites) are predicted to cause severe abnormalities in the protein product and are likely to represent null alleles. In addition, we have also analysed nine unrelated arOP patients from Costa Rica, where this disease is apparently much more frequent than elsewhere. All nine Costa Rican patients bore either or both of two missense mutations (G405R and R444L) in amino acid residues which are evolutionarily conserved from yeast to humans. The identification of ATP6i gene mutations in two families allowed us for the first time to perform prenatal diagnosis: both fetuses were predicted not to be affected and two healthy babies were born. This study contributes to the determination of genetic heterogeneity of arOP and allows further delineation of the other genetic defects causing this severe condition.
Asunto(s)
Mutación , Osteopetrosis/genética , ATPasas de Translocación de Protón Vacuolares/genética , Secuencia de Aminoácidos , Animales , Secuencia de Bases , Línea Celular , Canales de Cloruro/genética , Cromosomas Humanos Par 11 , Análisis Mutacional de ADN , Exones , Femenino , Genes Recesivos , Haplotipos , Humanos , Lactante , Recién Nacido , Intrones , Masculino , Datos de Secuencia Molecular , Osteopetrosis/enzimología , Reacción en Cadena de la Polimerasa , Homología de Secuencia de Aminoácido , Vacuolas/enzimología , Vacuolas/genéticaRESUMEN
BACKGROUND: In patients in whom syncopal episodes are mainly caused by occasional drops in heart rate, Sudden Rate Drop intervention feature intends to provide high rate intervention pacing. New Vitatron Medical B.V. pacemaker system Clarity DDDR, provides AN option FOR recognizing Sudden Rate Drop and responding by intervention pacing until it detects the recovering. MATERIAL AND METHODS: In patients with carotid sinus syndrome it is possible to provoke this situation BY sinus carotidus massage. We have implanted 10 of these devices in our center, 2 of which in patients with hypersensitive carotid sinus syndrome. In both patients, we activated sudden rate drop intervention on DDD mode pacing and applied protocol for testing the necessary level of Sudden Rate Drop Intervention Rate. Both patients gave their informed consent to be submitted to this testing. Pacemaker software assumes rate intervention level of 110 bpm. We tested our patients for rate levels of 90 and 110 bpm. Massaging the carotid sinus during 5 seconds, we provoked Sudden Rate Drop Intervention 10 times, in each patient, 5 times at intervention rate of 90 and 5 times at 110 bpm. Patients were unaware of the programmed intervention rate and were merely expected to report any different sensations experienced during the testing. RESULTS: In all 20 tests, pacemaker responded to sudden rate drop elicited by carotid sinus massage (100%), which was verified by selected event recordings. After the massage, neither of the patients registered any sensations at sudden rate drop intervention rate level of 90 bpm in a total od 10 tests (100%), while 8 out of 10 massages at 110 bpm intervention rate provoked palpitations (80%). On the grounds of this testing, we concluded that lowering of Sudden Rate Drop Intervention Rate Level from 110 BPM to 90 BPM does not affect the reliability of system reaction, but changes patient's awareness of heart beats. CONCLUSION: As a final conclusion, it should be said that basic prerogatives of a pacing system: safety and efficacy with minimal energy consumption, and in this case, quality of life option that a patients practically does not feel intervention when it occurs, are all met.
Asunto(s)
Seno Carotídeo/fisiopatología , Frecuencia Cardíaca/fisiología , Marcapaso Artificial , Síncope/fisiopatología , Síncope/terapia , Concienciación , Humanos , Diseño de PrótesisRESUMEN
A HPLC method associated with butyl-p-aminobenzoate derivatization has been developed for the analysis of a tetraglucose oligomer, Glcalpha1-6Glcalpha1-4Glcalpha1-4Glc, designated Glc(4), in biological fluids. This tetraglucose, normally excreted in the urine, has previously been shown to be elevated in a number of pathological conditions including Pompe disease (glycogen storage disease type II), which is caused by a deficiency of the lysosomal enzyme acid alpha-glucosidase. Concentrations of Glc(4) in both urine and plasma were established for the age ranges of <1, 1-5, 6-10, 11-20, and >20 years, both in normal individuals and in a cohort of 21 patients with enzymatically confirmed Pompe disease. The Glc(4) concentration decreased with age in both groups, but all the patients had elevated Glc(4) levels compared with age-matched controls. Electrospray tandem mass spectrometry was employed to establish the homogeneity of the HPLC peak for Glc(4) and to investigate the identity of other unusual oligosaccharides excreted in patient urine. Our results demonstrate that this method is suitable for application in clinical laboratories to help establish the diagnosis of Pompe disease.
Asunto(s)
Biomarcadores/análisis , Cromatografía Líquida de Alta Presión/métodos , Cromatografía Liquida/métodos , Enfermedad del Almacenamiento de Glucógeno Tipo II/diagnóstico , Enfermedad del Almacenamiento de Glucógeno Tipo II/metabolismo , Oligosacáridos/análisis , Adolescente , Adulto , Niño , Preescolar , Femenino , Humanos , Lactante , Masculino , Persona de Mediana Edad , Sensibilidad y EspecificidadRESUMEN
The acylcarnitines in plasma and blood spots of 23 patients with proven deficiency of long-chain 3-hydroxyacylcoenzyme A dehydrogenase were reviewed. Long-chain 3-hydroxyacylcarnitines of C14:1, C14, C16 and C18:1 chain length, and long-chain acylcarnitines of C12, C14:1, C14, C16, C18:2 and C18:1 chain length were elevated. Acetylcarnitine was decreased. In plasma, elevation of hydroxy-C18:1 acylcarnitine over the 95th centile of controls, in combination with an elevation of two of the three acylcarnitines C14, C14:1 and hydroxy-C16, identified over 85% of patients with high specificity (less than 0.1% false positive rate). High endogenous levels of long-chain acylcarnitines in normal erythrocytes reduced the diagnostic specificity in blood spots compared with plasma samples. The results were also diagnostic in asymptomatic patients, and were not influenced by genotype. Treatment with diet low in fat and high in medium-chain triglyceride decreased all disease-specific acylcarnitines, often to normal, suggesting that this assay is useful in treatment monitoring.
Asunto(s)
3-Hidroxiacil-CoA Deshidrogenasas/deficiencia , Carnitina/análogos & derivados , Carnitina/sangre , Plasma/química , 3-Hidroxiacil-CoA Deshidrogenasas/genética , Eritrocitos/química , Reacciones Falso Negativas , Femenino , Genotipo , Heterocigoto , Homocigoto , Humanos , Masculino , Mutación , Sensibilidad y EspecificidadRESUMEN
We report on 8 patients with a recently described novel subtype of congenital disorder of glycosylation type Ic (CDG-Ic). Their clinical presentation was mainly neurological with developmental retardation, muscular hypotonia, and epilepsy. Several symptoms commonly seen in CDG-Ia such as inverted nipples, abnormal fat distribution, and cerebellar hypoplasia were not observed. The clinical course is milder overall, with a better neurological outcome, than in CDG-Ia. The isoelectric focusing pattern of serum transferrin in CDG-Ia and CDG-Ic is indistinguishable. Interestingly, beta-trace protein in cerebrospinal fluid derived from immunoblot analysis of the brain showed a less pronounced hypoglycosylation pattern in CDG-Ic patients than in CDG-Ia patients. Analysis of lipid-linked oligosaccharides revealed an accumulation of Man9GlcNAc2 intermediates due to dolichol pyrophosphate-Man9GlcNAc2 alpha-1,3 glucosyltransferase deficiency. All patients were homozygous for an A333V mutation.
Asunto(s)
Encéfalo/metabolismo , Trastornos Congénitos de Glicosilación/fisiopatología , Retículo Endoplásmico/metabolismo , Glucosiltransferasas/deficiencia , Polisacáridos/biosíntesis , Sustitución de Aminoácidos , Encéfalo/patología , Secuencia de Carbohidratos , Niño , Preescolar , Trastornos Congénitos de Glicosilación/genética , Trastornos Congénitos de Glicosilación/metabolismo , Diagnóstico Diferencial , Epilepsia/fisiopatología , Femenino , Glucosiltransferasas/genética , Glicosilación , Homocigoto , Humanos , Lactante , Discapacidad Intelectual/fisiopatología , Imagen por Resonancia Magnética , Masculino , Datos de Secuencia Molecular , Músculos/fisiopatología , Mutación Missense , Núcleo Familiar , Oligosacáridos/biosíntesis , Oligosacáridos/química , Polisacáridos/genética , Gemelos MonocigóticosRESUMEN
Mitochondrial fatty acid oxidation disorders cause hypoglycaemia, hepatic dysfunction, myopathy, cardiomyopathy and encephalopathy. Despite their recognition for more than 15 years, diagnosis and treatment remain difficult. To help design rational diagnostic and therapeutic strategies, we studied the pathophysiology of accumulating metabolites in a whole-cell system. Acylcarnitines were quantified in cells and media of cultured fibroblasts after incubation with L-carnitine and fatty acids. Following incubation with palmitate, long-chain 3-hydroxyacyl-CoA dehydrogenase (LCHAD)-deficient fibroblasts compared with controls showed elevation of hydroxypalmitoyl- and palmitoyl-carnitine and reduction of C10- and shorter acylcarnitines, and following incubation with linoleate an increase in C14:2-, C18:2- and hydroxy-C18:2- acylcarnitines and reduction in C10:1-acylcarnitines. Hydroxyacylcarnitines remained more intracellular compared to corresponding saturated acylcarnitines. Incubation with decanoate and octanoate showed absence of hydroxylated acylcarnitines and correction of secondary metabolic disturbances, suggesting that optimal treatment should include medium-chain triglycerides of these chain lengths. Fibroblasts of patients with other fatty acid oxidation disorders showed distinct elevations of disease-specific acylcarnitines. This acylcarnitine analysis allows the diagnosis of LCHAD deficiency and its differentiation from other fatty acid oxidation disorders, which can pose difficulties in vivo. The strategy has allowed in-depth analysis with different substrates, providing suggestions for the rational design of treatment trials.
Asunto(s)
3-Hidroxiacil-CoA Deshidrogenasas/deficiencia , Carnitina/análogos & derivados , Ácidos Grasos/metabolismo , Carnitina/análisis , Células Cultivadas , Fibroblastos/química , Humanos , Microcuerpos/metabolismo , Oxidación-ReducciónRESUMEN
We present four patients with typical neonatal onset non-ketotic hyperglycinemia (NKH) who developed hydrocephalus requiring shunting in early infancy. Brain imaging revealed acute hydrocephalus, a megacisterna magna or posterior fossa cyst, pronounced atrophy of the white matter, and an extremely thin corpus callosum in all. The three older patients had profound developmental disabilities. This suggests that the development of hydrocephalus in NKH is an additional poor prognostic sign.
Asunto(s)
Hidrocefalia/diagnóstico por imagen , Hidrocefalia/patología , Hiperglicinemia no Cetósica/diagnóstico por imagen , Hiperglicinemia no Cetósica/patología , Enfermedad Aguda , Encéfalo/diagnóstico por imagen , Encéfalo/patología , Femenino , Humanos , Recién Nacido , Imagen por Resonancia Magnética , Masculino , Tomografía Computarizada por Rayos XRESUMEN
A patient with severe pyruvate carboxylase deficiency presented at age 11 weeks with metabolic decompensation after routine immunization. She was comatose, had severe lactic acidemia (22 mM) and ketosis, low aspartate and glutamate, elevated citrulline and proline, and mild hyperammonemia. Head magnetic resonance imaging showed subdural hematomas and mild generalized brain atrophy. Biotin-unresponsive pyruvate carboxylase deficiency was diagnosed. To provide oxaloacetate, she was treated with high-dose citrate (7.5 mol/kg(-1)/day(-1)), aspartate (10 mmol/kg(-1)/day(-1)), and continuous drip feeding. Lactate and ketones diminished dramatically, and plasma amino acids normalized, except for arginine, which required supplementation. In the cerebrospinal fluid (CSF), glutamine remained low and lysine elevated, showing the treatment had not normalized brain chemistry. Metabolic decompensations, triggered by infections or fasting, diminished after the first year. They were characterized by severe lactic and ketoacidosis, hypernatremia, and a tendency to hypoglycemia. At age 3(1/2) years she has profound mental retardation, spasticity, and grand mal and myoclonic seizures only partially controlled by anticonvulsants. The new treatment regimen has helped maintain metabolic control, but the neurological outcome is still poor.